Vigil Neuroscience Inc. (NASDAQ: VIGL)
$4.23
-0.1200 ( -2.76% ) 255.0K
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
Market Data
Open
$4.23
Previous close
$4.35
Volume
255.0K
Market cap
$157.85M
Day range
$4.16 - $4.48
52 week range
$2.47 - $9.98
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 63 | May 07, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |
8-k | 8K-related | 15 | May 07, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |